## Supplementary material on-line

Novel pathways in pathobiology of human abdominal aortic aneurysms
I Hinterseher, R Erdman, JR Elmore, E Stahl, MC Pahl, K Derr, A Golden, JH Lillvis, MC Cindric, K Jackson, WD Bowen, CM Schworer, MA Chernousov, DP Franklin, JL Gray, RP Garvin, Z Gatalica, DJ Carey, G Tromp, and H Kuivaniemi

This file contains 3 tables (Table S1, S2 and S3) and Fig. S1
Table S1. Human infrarenal abdominal aortic tissue samples used in the study

| Case ID | Classifi cation | Sex | Age <br> (y) | Cause of Death | Microarray | PCR <br> Array | $\begin{gathered} \text { Western } \\ \text { Blot } \end{gathered}$ | IHC |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A1-F | AAA | F | 82 |  | $\sqrt{*}$ |  |  |  |
| A2-F | AAA | F | 68 |  | $\sqrt{*}$ |  |  |  |
| A3-F | AAA | F | 64 |  | $\sqrt{*}$ |  |  |  |
| A2-M | AAA | M | 63 |  | $\sqrt{*}$ |  |  |  |
| A3-M | AAA | M | 67 |  | $\sqrt{*}$ |  |  |  |
| A4-M | AAA | M | 63 |  | $\sqrt{*}$ |  |  |  |
| GHS020200 | AAA | M | 82 |  | $\sqrt{ }$ |  |  |  |
| GHS020400 | AAA | M | 76 |  | $\sqrt{ }$ |  |  |  |
| GHS200306 | AAA | M | 70 |  | $\checkmark$ |  |  |  |
| GHS200308 | AAA | M | 74 |  | $\sqrt{ }$ |  |  |  |
| WSU052 | AAA | M | 70 |  |  |  |  | $\checkmark$ |
| WSU075 | AAA | M | 67 |  |  |  |  | $\sqrt{ }$ |
| WSU068 | AAA | M | 72 |  |  |  |  | $\checkmark$ |
| GHS01 | AAA | M | 67 |  |  | $\checkmark$ |  | $\checkmark$ |
| GHS02 | AAA | F | 63 |  |  | $\checkmark$ |  |  |
| GHS05 | AAA | M | 64 |  |  | $\sqrt{ }$ |  | $\checkmark$ |
| GHS07 | AAA | F | 65 |  |  | $\checkmark$ | $\checkmark$ |  |
| GHS11 | AAA | F | 61 |  |  | $\sqrt{ }$ |  |  |
| GHS12 | AAA | M | 70 |  |  | $\checkmark$ |  |  |
| GHS13 | AAA | M | 78 |  |  | $\sqrt{ }$ |  |  |
| GHS14 | AAA | M | 75 |  |  | $\checkmark$ |  |  |
| GHS15 | AAA | M | 66 |  |  | $\sqrt{ }$ |  |  |
| GHS19 | AAA | M | 66 |  |  | $\sqrt{ }$ |  |  |
| GHS32 | AAA | C | 64 |  |  |  | $\checkmark$ |  |
| GHS48 | AAA | C | 65 |  |  |  | $\checkmark$ |  |
| GHS68 | AAA | C | 61 |  |  |  | $\sqrt{ }$ |  |
| GHS200210 | AAA | M | 60 |  |  | $\checkmark$ |  |  |
| GHS200212 | AAA | M | 73 |  |  | $\sqrt{ }$ |  |  |
| GHS200214 | AAA | M | 60 |  |  | $\checkmark$ |  |  |
| GHS200219 | AAA | M | 67 |  |  | $\sqrt{ }$ |  |  |
| GHS200305 | AAA | M | 64 |  |  | $\sqrt{ }$ |  |  |
| C1-F | Control | F | 74 | Cancer | $\sqrt{*}$ |  |  |  |
| C2-F | Control | F | 52 | Cancer | $\sqrt{*}$ |  |  |  |
| C3-F | Control | F | 84 | Aortic arch dissection | $\sqrt{*}$ |  |  |  |
| C1-M | Control | M | 65 | Peritonitis | $\sqrt{*}$ |  |  |  |
| C2-M | Control | M | 59 | Cancer | $\sqrt{*}$ |  |  |  |
| C3-M | Control | M | 52 | Liver cirrhosis | $\sqrt{*}$ |  |  |  |
| C4-M | Control | M | 73 | Cancer | $\sqrt{*}$ |  |  |  |
| GHS200105 | Control | M | 21 | Trauma | $\checkmark$ |  |  |  |
| GHS200401 | Control | F | 53 | Cancer | $\checkmark$ |  |  |  |
| GHS024200 | Control | M | 53 | NA | $\checkmark$ |  |  |  |
| NDRI56735 | Control | F | 54 | Cancer | $\sqrt{ }$ |  | $\checkmark$ |  |
| NDRI56724 | Control | F | 77 | Natural |  | $\checkmark$ |  |  |
| NDRI57017 | Control | F | 78 | Cardiovascular |  | $\sqrt{ }$ | $\sqrt{ }$ |  |


| NDRI57054 | Control | M | 69 | Cardiovascular | $\sqrt{ }$ | $\sqrt{ }$ |  |
| :--- | :--- | :---: | :--- | :---: | :---: | :---: | :---: |
| NDRI57179 | Control | F | 57 | Respiratory failure | $\sqrt{ }$ |  |  |
| NDRI57110 | Control | M | 69 | Cardiovascular | $\sqrt{ }$ |  |  |
| NDRI66274 | Control | M | 61 | Cardiovascular | $\sqrt{ }$ |  |  |
| NDRI66279 | Control | M | 64 | Cancer | $\sqrt{ }$ |  |  |
| NDRI66324 | Control | M | 67 | Cancer | $\sqrt{ }$ |  |  |
| NDRI66747 | Control | M | 57 | Cardiovascular | $\sqrt{ }$ |  |  |
| NDRI66799 | Control | M | 67 | Respiratory |  | $\sqrt{ }$ |  |
| ME-01-05 | Control | M | 53 | NA | $\sqrt{ }$ |  |  |
| ME-02-05 | Control | M | 78 | Cardiovascular | $\sqrt{ }$ | $\sqrt{ }$ |  |
| ME-05-01 | Control | F | 69 | Trauma | $\sqrt{ }$ |  |  |
| ME-05-03 | Control | M | 54 | Cardiovascular |  |  |  |
| ME-05-05 | Control | F | 59 | Cardiovascular | $\sqrt{ }$ |  |  |
| ME-10-01 | Control | F | 88 | Trauma | $\sqrt{ }$ |  |  |
| ME-10-03 | Control | M | 44 | Overdose |  |  |  |

NA, Not available.
All donors were Caucasian.
Samples were stored in RNAlater (Ambion, Austin, TX), in phosphate-buffered formalin (and embedded in paraffin), or snap-frozen in liquid nitrogen.
*These samples were used in the previous microarray study [1].
For the microarray experiment [1], the summary statistics are:

- AAA group $(n=6$ : mean age $=67.8+/-7.3$, Median $=65.5$, Male $:$ Female $=3: 3$
- Control group $(n=7)$ : mean age $=65.6+/-12.1$, Median $=65$, Male $:$ Female $=4: 3$
- Comparison of ages in the study groups: $P=0.69$ (two-tailed t-test, unequal variance)

For the second microarray experiment reported in this study, the summary statistics are:

- $\quad$ AAA group $(\mathrm{N}=4)$ : mean age $=75+/-5.0$, Median $=74$, Male:Female $=4: 0$
- Control group $(\mathrm{N}=4)$ : mean age $=45.3+/-16.2$, Median $=53$, Male:Female $=2: 2$
- Comparison of ages in the study groups: $\mathrm{p}=0.03$ (two-tailed t -test, unequal variance)

For the PCRArrays, the summary statistics are:

- AAA group $(n=15)$ : mean age $=66.7+/-5.4 ;$ median $=66 ;$ Male:Female $=12: 3$
- Control group $(n=15)$ : mean age $=66.6+/-11.1 ;$ median $=67$; Male:Female $=10: 5$
- Comparison of ages in the study groups: $P=0.98$ (two-tailed t-test, unequal variance)


## Table S2. Design of custom PCRArray, the "AAA-chip", with 43 genes of interest and 5 controls

| Gene <br> Symbol | Gene ID | RefSeq $_{*}$ <br> Number $^{*}$ | RT $^{2}$ Catalog <br> Number | Size of PCR <br> Band <br> $(\mathrm{bp})$ | Reference <br> Position $^{\dagger}$ | Splice Variant Amplicons |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |


| GATM | $\underline{2628}$ | NM_001482 | PPH09960 | 84 | 1682 | NA |
| :--- | ---: | :--- | :--- | ---: | ---: | ---: |
| GPR65 | $\underline{8477}$ | NM-003608 | PPH12137 | 105 | 578 | NA |
| HSPB2 | $\underline{3316}$ | NM-001541 | PPH01204 | 109 | 320 | NA |
| IL10RA | $\underline{3587}$ | NM-001558 | PPH00591 | 101 | 3400 | NR026691 |
| ITGA10 | $\underline{8515}$ | NM_003637 | PPH00635 | 92 | 3433 | NA |
| ITGA5 | $\underline{3678}$ | NM-002205 | PPH00176 | 87 | 2690 | NA |
| LARP6 | $\underline{55323}$ | NM-197958 | PPH19780 | 117 | 153 | NM018357 |
| LCP2 | $\underline{3937}$ | NM_005565 | PPH01634 | 154 | 1664 | NA |
| LDOC1 | $\underline{23641}$ | NM_012317 | PPH09280 | 83 | 170 | NA |
| LMOD1 | $\underline{25802}$ | NM_012134 | PPH10165 | 122 | 3126 | NA |
| LYZ | $\underline{4069}$ | NM-000239 | PPH14748 | 105 | 295 | NA |
| MARCKS | $\underline{4082}$ | NM_002356 | PPH05579 | 158 | 1457 | NA |
| MFGE8 | $\underline{4240}$ | NM-005928 | PPH07218 | 88 | 1217 | NM001114614 |
| MX2 | $\underline{4600}$ | NM-002463 | PPH01326 | 164 | 2818 | NA |
| NCF4 | $\underline{4689}$ | NM-000631 | PPH14176 | 174 | 1312 | NM013416 |
| NPTX2 | $\underline{4885}$ | NM_002523 | PPH07197 | 149 | 1278 | NA |
| NTRK3 | $\underline{4916}$ | NM_002530 | PPH01551 | 173 | 1584 | NM001007156, |
| PDE8B | $\underline{8622}$ | NM_003719 | PPH10098 |  | 92 | 2432 |

*The RefSeq Accession number refers to the representative sequence used to design the primers.
${ }^{\dagger}$ The Reference Position is a position within the sequence of the amplicon relative to the start of the relevant RefSeq sequence.
${ }^{\S}$ The primers used for the assay can also generate amplicons from the listed splice variants.
Information was generated from: http://sabiosciences.com/RT2PCR.php. Assays can be purchased from SABioscience-Qiagen. A custom PCRArray was designed with 43 genes of interest selected from our two microarray studies [1], and run on RNA samples isolated from a set of 15 human AAA samples and 15 control abdominal aorta samples (Supplementary material online, Table S1). cDNA synthesis was performed using the $\mathrm{RT}^{2}$ first strand kit (SABiosciences-Qiagen, Frederick, MD). Expression of the 43 genes was analyzed in a 96 -well plate using a custom $\mathrm{RT}^{2}$ Profiler PCR array (SABiosciences-Qiagen, Frederick, MD). The assays were run according to manufacturer's instructions (SABiosciences-Qiagen, Frederick, MD) in a 7500 Fast Real Time PCR system (Applied Biosystems, Carlsbad, CA). Two housekeeping genes (GAPDH and RPL13A) were measured to standardize the results. After PCR, amplification plots were inspected and baselines and threshold values were set according to the manufacturer's recommendations (SABiosciences-Qiagen, Frederick, MD). The threshold cycle numbers $\left(\mathrm{C}_{\mathrm{T}}\right)$ were computed for each well. For calculating the $\Delta \mathrm{C}_{\mathrm{T}}$ values for each well and processing the results further, the online analysis tool provided by SABiosciences-Qiagen was used. Briefly, the amplification $C_{T}$ values from the housekeeping genes were subtracted from the gene-of-interest $C_{T}$ values for each sample to calculate the $\Delta \mathrm{C}_{\mathrm{T}}$.

Table S3. Primary antibodies used for Western blots and immunohistochemical staining

| Gene Symbol | Protein name | Antibody catalog number | Vendor | Species | WB Dilution | IHC Dilution |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| ACTB | ACTB | A1978 | Sigma | Mouse monoclonal | 1:1000 |  |
| PTPRC | PTPRC | HPA000440 | Sigma-Aldrich | Rabbit | 1:100 | 1:50 |
| PTPRC | CD45 | MS-355-R7 | Thermo | polyclonal Mouse monoclonal | 1:200 | 1:200 |
| CD4 | CD4 | M7310 | Dako | Mouse | 1:200 |  |
| CD4 | CD4 | 790-4423 | Ventana | monoclonal Rabbit monoclonal |  | as provided by company |
| GATM | GATM | HPA026077 | Sigma-Aldrich | Rabbit polyclonal | 1:200 | 1:115 |
| ITGA5 | ITGA5 | AB1928 | Chemicon | Rabbit polyclonal |  | 1:188 |
| ITGA10* | ITGA10 | sc-161740 | Santa Cruz | Goat polyclonal | 1:200 |  |
| $L Y Z{ }^{\dagger}$ | LYZ | A0099 | DAKO | Rabbit polyclonal |  | 1:401 |
| FOSB | FOSB | sc-48 | Santa Cruz | Rabbit polyclonal |  | 1:240 |
| MFGE8* | MFGE8 | sc-8029 | Santa Cruz | Mouse monoclonal |  | 1:100 |
| BLNK | BLNK | sc-15345 | Santa Cruz | Rabbit polyclonal |  | 1:51 |
| DUSP6 | MKP-3 | sc-28902 | Santa Cruz | Rabbit polyclonal |  | 1:80 |
| CXCR4 | Fusin | sc-9046 | Santa Cruz | Rabbit polyclonal |  | 1:120 |
| PLEK | PLEK | sc-100813 | Santa Cruz | Mouse monoclonal |  | 1:50 |

WB, western blot; IHC, immunohistochemical staining
*Antibody did not perform well and no results are reported here.
${ }^{\dagger}$ For staining with LYZ antibody tissues were pre-treated with proteinase K according to DAKO protocol.

## Reference:

1 Lenk GM, Tromp G, Weinsheimer S, Gatalica Z, Berguer R, Kuivaniemi H: Whole genome expression profiling reveals a significant role for immune function in human abdominal aortic aneurysms. BMC Genomics 2007;8:237.

Fig. 1S (on next page). A network of the 38 differentially expressed genes in AAA. The analysis, which was carried out with Ingenuity Pathways Analysis software version 9.0 (IPA, Ingenuity® Systems, Mountain View, CA, www.ingenuity.com), yielded four networks, which were then merged. The differentially expressed genes are highlighted in grey. Molecules are represented as nodes, and the biological relationship between two nodes is represented as a line. All lines are supported by at least one literature citation or from canonical information stored in the Ingenuity Pathways Knowledge Base. Nodes are displayed using various shapes that represent the functional class of the gene product. Lines are displayed with various labels that describe the nature of the relationship between the nodes (e.g., P for phosphorylation, T for transcription).


